Reslizumab (Cinqair)

Cinqair (reslizumab) is covered as add‑on maintenance therapy for adults ≥18 with severe eosinophilic asthma who have pretreatment blood eosinophils ≥400 cells/mcL, are current non‑smokers, have uncontrolled disease despite appropriate controller therapy (high‑dose ICS+LABA, or leukotriene modifier/theophylline for the prior year, or systemic corticosteroids ≥50% of the prior year), with dosing 3 mg/kg IV every 4 weeks and a 12‑month approval. Key requirements: prescriber must be an allergist/immunologist/pulmonologist, documentation of diagnosis, labs, prior/concurrent therapies, weight/infusion records, and reauthorization requires documented reduction in asthma exacerbations; no compendial off‑label uses are listed.

"For reauthorization: documentation showing reduction in incidence of asthma exacerbations (response to therapy)."

Sign up to see full coverage criteria, indications, and limitations.